Bio-Thera Solutions has signed an exclusive licence and commercialisation agreement with Intas Pharmaceuticals for the Simponi (golimumab) biosimilar, BAT2506 in the US. Bio-Thera will develop ...
Golimumab is a human IgG1 monoclonal antibody that targets tumor necrosis factor alpha (TNF- α), a pro-inflammatory molecule. According to Bio-Thera, binding of golimumab to TNF-α results in ...
Biologics are large-molecule medications created in a lab ... such as Humira (adalimumab), Simponi (golimumab), Remicade ...
BAT2506, a tumor necrosis factor-alpha (TNF-alpha) blocker, is a Phase 3 biosimilar candidate to Simponi ® (golimumab) Agreement will provide Accord BioPharma with future U.S. commercialization ...
AVT05 is a biosimilar candidate to Johnson & Johnson's (JNJ) Simponi and Simponi Aria, also known by their generic name, golimumab, which are approved to treat a variety of inflammatory conditions.